Turning Point Brands Announces Second Quarter 2022 Results
Turning Point Brands (TPB) reported a 16.1% decline in net sales to $102.9 million for Q2 2022 compared to Q2 2021. Gross profit dropped 14.2% to $51.5 million, and net income fell 64.7% to $5.4 million. Adjusted EBITDA also decreased by 17.6% to $24.7 million. Despite challenges, Zig-Zag and Stoker’s segments remained stable, with Zig-Zag achieving a slight decrease in sales of 2.1% and Stoker’s rising by 0.7%. NewGen Products saw a significant 45.1% decline in sales. The company revised its full-year outlook due to market uncertainties.
- Zig-Zag products maintained a strong position in the U.S. rolling paper market despite overall sales decline.
- Stoker's products segment experienced a slight net sales increase of 0.7%.
- Continued share repurchases indicate strong capital management.
- Overall net sales decreased by 16.1%, impacting revenue significantly.
- Net income declined by 64.7%, which may concern investors.
- NewGen products experienced a sharp 45.1% decline in sales, raising regulatory concerns.
- Stoker’s continues to gain share with Zig-Zag’s US rolling papers and e-commerce subsegment recording another quarter of double digit growth
Q2 2022 vs. Q2 2021
-
Net sales decreased 16.1 percent to
$102.9 million - Combined net sales for Zig-Zag and Stoker’s Products demonstrated resilience decreasing 0.9 percent for the quarter
- NewGen net sales declined by 45.1 percent (declined 2.1 percent sequentially)
-
Gross profit decreased 14.2 percent to
$51.5 million -
Net income decreased 64.7 percent to
$5.4 million -
Adjusted EBITDA decreased 17.6 percent to
(see Schedule A for a reconciliation to net income)$24.7 million -
Diluted EPS of
and Adjusted Diluted EPS of$0.30 as compared to$0.70 and$0.73 in the same period one year ago, respectively (see Schedule B for a reconciliation to Diluted EPS)$0.84
“We are pleased with the stable performance of both the Zig-Zag and Stoker’s segments during the quarter in light of a heightened inflationary environment for our customers with rising prices at the pump impacting consumer traffic in convenience stores. While overall sales decreased 16 percent from the previous year, Zig-Zag and Stoker’s sales were steady despite weakness in the wraps and loose leaf subsegments. Zig-Zag maintained its leading positions in both the roll-your-own paper and cigar wraps markets while Stoker’s MST experienced accelerated share gains driven by consumer trade-down to the value category. Despite NewGen revenue decreasing 45 percent from last year, the segment remained relatively stable from the previous quarter and profitable as we continue to monitor FDA regulatory developments,” said
Zig-Zag Products Segment (45 percent of total net sales in the quarter)
For the second quarter, Zig-Zag Products remained broadly in-line with a record performance in 2021 with net sales decreasing 2.1 percent to
For the quarter, the Zig-Zag Products segment gross profit decreased 4.7 percent to
“Paper cones and Zig-Zag’s e-commerce business once again drove the growth within our
Stoker’s Products Segment (33 percent of total net sales in the quarter)
For the second quarter, Stoker’s Products net sales increased 0.7 percent to
For the quarter, the Stoker’s Products segment gross profit decreased 0.4 percent to
“Stoker’s continued to outperform the market with share gains in both the MST and loose-leaf chewing tobacco categories during the quarter,” continued Purdy. “With the current inflationary environment accelerating the secular down-trading trends in the industry, Stoker’s remains well positioned within its categories as a leading value brand.”
NewGen Products Segment (22 percent of total net sales in the quarter)
For the second quarter, NewGen Products net sales decreased 45.1 percent to
For the quarter, the NewGen Products segment gross profit decreased 50.6 percent to
“Despite another challenging quarter further impacted by new regulation around synthetic nicotine products, our vape business remained profitable,” concluded Purdy. “Meanwhile, our distribution capabilities continued to improve through the quarter as we position our business for a post-PMTA environment while our vapor products’ applications remain under FDA review.”
Performance Measures in the Second Quarter
Second quarter consolidated selling, general and administrative (“SG&A”) expenses were
The second quarter SG&A included the following notable items:
-
of restructuring expenses compared to none in the previous year$0.3 million -
of ERP / CRM scoping expenses and duplicative system costs compared to none in the previous year$0.9 million -
of stock options, restricted stock and incentive expense compared to$1.5 million in the year-ago period$2.8 million -
of transaction expenses compared to$0.4 million in the year-ago period$0.7 million -
of FDA PMTA-related expenses compared to$2.0 million in the year-ago period$0.6 million -
from the accounting consolidation of Turning Point Brands Canada compared to$1.6 million in the year-ago period with the increase driven by the inclusion of a full quarter of the DVW acquisition in the current period$1.1
Total gross debt as of
During the quarter, the Company spent
2022 Outlook
Due to the uncertain macro environment and slower than expected improvement in our NewGen Products segment, the Company now expects the following full-year 2022 results:
-
Zig-Zag Products sales of
to$193 (compared to previous outlook of$200 million to$193 )$203 million -
Stoker’s Products sales of
to$127 $133 million -
Consolidated adjusted EBITDA of
to$97 $103 million
Earnings Conference Call
As previously disclosed, a conference call with the investment community to review TPB’s financial results has been scheduled for
Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles in
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intend," "plan" and "will" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. As a result, these statements are not guarantees of future performance and actual events may differ materially from those expressed in or suggested by the forward-looking statements. Any forward-looking statement made by TPB in this press release, its reports filed with the
Financial Statements Follow:
Consolidated Statements of Income | ||||||||
(dollars in thousands except share data) | ||||||||
(unaudited) | ||||||||
Three Months Ended |
||||||||
2022 |
|
2021 |
||||||
Net sales | $ |
102,925 |
|
$ |
122,643 |
|
||
Cost of sales |
|
51,456 |
|
|
62,670 |
|
||
Gross profit |
|
51,469 |
|
|
59,973 |
|
||
Selling, general, and administrative expenses |
|
33,323 |
|
|
35,094 |
|
||
Operating income |
|
18,146 |
|
|
24,879 |
|
||
Interest expense, net |
|
5,144 |
|
|
5,522 |
|
||
Investment loss (income) |
|
6,227 |
|
|
(110 |
) |
||
Income before income taxes |
|
6,775 |
|
|
19,467 |
|
||
Income tax expense |
|
1,569 |
|
|
4,424 |
|
||
Consolidated net income |
|
5,206 |
|
|
15,043 |
|
||
Net loss attributable to non-controlling interest |
|
(218 |
) |
|
(312 |
) |
||
Net income attributable to |
$ |
5,424 |
|
$ |
15,355 |
|
||
Basic income per common share: | ||||||||
Net income attributable to |
$ |
0.30 |
|
$ |
0.81 |
|
||
Diluted income per common share: | ||||||||
Net income attributable to |
$ |
0.30 |
|
$ |
0.73 |
|
||
Weighted average common shares outstanding: | ||||||||
Basic |
|
18,063,259 |
|
|
18,975,522 |
|
||
Diluted |
|
21,443,279 |
|
|
22,489,662 |
|
||
Supplemental disclosures of statements of income information: | ||||||||
Excise tax expense | $ |
6,141 |
|
$ |
7,687 |
|
||
FDA fees | $ |
171 |
|
$ |
180 |
|
||
Consolidated Balance Sheets | |||||||||
(dollars in thousands except share data) | |||||||||
(unaudited) |
|
|
|||||||
|
|
|
|||||||
ASSETS | 2022 |
|
2021 |
||||||
Current assets: | |||||||||
Cash | $ |
107,429 |
|
$ |
128,320 |
|
|||
Accounts receivable, net of allowances of |
|
9,177 |
|
|
6,496 |
|
|||
Inventories |
|
115,129 |
|
|
87,607 |
|
|||
Other current assets |
|
27,353 |
|
|
26,746 |
|
|||
Total current assets |
|
259,088 |
|
|
249,169 |
|
|||
Property, plant, and equipment, net |
|
22,376 |
|
|
18,650 |
|
|||
Deferred income taxes |
|
2,111 |
|
|
1,363 |
|
|||
Right of use assets |
|
13,749 |
|
|
15,053 |
|
|||
Deferred financing costs, net |
|
335 |
|
|
388 |
|
|||
|
162,385 |
|
|
162,333 |
|
||||
Other intangible assets, net |
|
86,566 |
|
|
87,485 |
|
|||
Master Settlement Agreement (MSA) escrow deposits |
|
29,224 |
|
|
31,720 |
|
|||
Other assets |
|
28,475 |
|
|
35,399 |
|
|||
Total assets | $ |
604,309 |
|
$ |
601,560 |
|
|||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||
Current liabilities: | |||||||||
Accounts payable | $ |
14,436 |
|
$ |
7,361 |
|
|||
Accrued liabilities |
|
34,560 |
|
|
32,937 |
|
|||
Other current liabilities |
|
38 |
|
|
38 |
|
|||
Total current liabilities |
|
49,034 |
|
|
40,336 |
|
|||
Notes payable and long-term debt |
|
415,410 |
|
|
414,172 |
|
|||
Lease liabilities |
|
11,934 |
|
|
13,336 |
|
|||
Total liabilities |
|
476,378 |
|
|
467,844 |
|
|||
Commitments and contingencies | |||||||||
Stockholders' equity: | |||||||||
Preferred stock; |
|
- |
|
|
- |
|
|||
Common stock, voting, |
|
198 |
|
|
197 |
|
|||
Common stock, nonvoting, |
|
- |
|
|
- |
|
|||
Additional paid-in capital |
|
110,563 |
|
|
108,811 |
|
|||
Cost of repurchased common stock (1,907,294 shares at |
|
(68,287 |
) |
|
(48,869 |
) |
|||
Accumulated other comprehensive loss |
|
(2,064 |
) |
|
(195 |
) |
|||
Accumulated earnings |
|
85,641 |
|
|
71,460 |
|
|||
Non-controlling interest |
|
1,880 |
|
|
2,312 |
|
|||
Total stockholders' equity |
|
127,931 |
|
|
133,716 |
|
|||
Total liabilities and stockholders' equity | $ |
604,309 |
|
$ |
601,560 |
|
|||
Consolidated Statements of Cash Flows | ||||||||
(dollars in thousands) | ||||||||
(unaudited) | ||||||||
Six Months Ended |
||||||||
2022 |
|
2021 |
||||||
Cash flows from operating activities: | ||||||||
Consolidated net income | $ |
15,977 |
|
$ |
26,570 |
|
||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Loss on extinguishment of debt |
|
- |
|
|
5,706 |
|
||
Gain on sale of property, plant, and equipment |
|
(8 |
) |
|
(2 |
) |
||
Depreciation expense |
|
1,750 |
|
|
1,546 |
|
||
Amortization of other intangible assets |
|
919 |
|
|
954 |
|
||
Amortization of deferred financing costs |
|
1,291 |
|
|
1,251 |
|
||
Deferred income tax (benefit) expense |
|
(146 |
) |
|
1,027 |
|
||
Stock compensation expense |
|
2,661 |
|
|
4,263 |
|
||
Noncash lease income |
|
(6 |
) |
|
(19 |
) |
||
Loss (gain) on investments |
|
6,258 |
|
|
(34 |
) |
||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable |
|
(2,673 |
) |
|
3,955 |
|
||
Inventories |
|
(27,499 |
) |
|
(12,007 |
) |
||
Other current assets |
|
(598 |
) |
|
813 |
|
||
Other assets |
|
624 |
|
|
599 |
|
||
Accounts payable |
|
7,240 |
|
|
1,423 |
|
||
Accrued liabilities and other |
|
1,359 |
|
|
1,370 |
|
||
Net cash provided by operating activities | $ |
7,149 |
|
$ |
37,415 |
|
||
Cash flows from investing activities: | ||||||||
Capital expenditures | $ |
(5,694 |
) |
$ |
(2,170 |
) |
||
Acquisitions, net of cash acquired |
|
- |
|
|
(3,419 |
) |
||
Payments for investments |
|
- |
|
|
(8,657 |
) |
||
Restricted cash, MSA escrow deposits |
|
(10,078 |
) |
|
(20,147 |
) |
||
Proceeds on the sale of property, plant and equipment |
|
63 |
|
|
2 |
|
||
Net cash used in investing activities | $ |
(15,709 |
) |
$ |
(34,391 |
) |
||
Cash flows from financing activities: | ||||||||
Proceeds from Senior Secured Notes | $ |
- |
|
$ |
250,000 |
|
||
Payments of 2018 first lien term loan |
|
- |
|
|
(130,000 |
) |
||
Settlement of interest rate swaps |
|
- |
|
|
(3,573 |
) |
||
Payment of dividends |
|
(2,181 |
) |
|
(2,006 |
) |
||
Payments of financing costs |
|
- |
|
|
(6,921 |
) |
||
Exercise of options |
|
475 |
|
|
886 |
|
||
Redemption of options |
|
(155 |
) |
|
(2,111 |
) |
||
Redemption of performance restricted stock units |
|
(1,228 |
) |
|
- |
|
||
Common stock repurchased |
|
(19,418 |
) |
|
(14,086 |
) |
||
Net cash provided by (used in) financing activities | $ |
(22,507 |
) |
$ |
92,189 |
|
||
Net (decrease) increase in cash | $ |
(31,067 |
) |
$ |
95,213 |
|
||
Effect of foreign currency translation on cash | $ |
56 |
|
$ |
315 |
|
||
Cash, beginning of period: | ||||||||
Unrestricted |
|
128,320 |
|
|
41,765 |
|
||
Restricted |
|
15,155 |
|
|
35,074 |
|
||
Total cash at beginning of period |
|
143,475 |
|
|
76,839 |
|
||
Cash, end of period: | ||||||||
Unrestricted |
|
107,429 |
|
|
157,474 |
|
||
Restricted |
|
5,035 |
|
|
14,893 |
|
||
Total cash at end of period | $ |
112,464 |
|
$ |
172,367 |
|
||
Non-GAAP Financial Measures
To supplement our financial information presented in accordance with generally accepted accounting principles in
We define “EBITDA” as net income before interest expense, loss on extinguishment of debt, provision for income taxes, depreciation and amortization. We define “Adjusted EBITDA” as net income before interest expense, loss on extinguishment of debt, provision for income taxes, depreciation, amortization, other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted diluted EPS” as diluted earnings per share excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Operating Income” as operating income excluding other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance.
Non-
In accordance with
Schedule A | ||||||
Reconciliation of GAAP Net Income to Adjusted EBITDA | ||||||
(dollars in thousands) | ||||||
(unaudited) | ||||||
Three Months Ended |
||||||
|
||||||
2022 |
|
2021 |
||||
Net income attributable to |
$ |
5,424 |
$ |
15,355 |
||
Add: | ||||||
Interest expense, net |
|
5,144 |
|
5,522 |
||
Income tax expense |
|
1,569 |
|
4,424 |
||
Depreciation expense |
|
879 |
|
758 |
||
Amortization expense |
|
456 |
|
479 |
||
EBITDA | $ |
13,472 |
$ |
26,538 |
||
Components of Adjusted EBITDA |
||||||
Corporate restructuring (a) |
|
270 |
|
- |
||
ERP/CRM (b) |
|
861 |
|
- |
||
Stock options, restricted stock, and incentives expense (c) |
|
1,502 |
|
2,764 |
||
Transactional expenses (d) |
|
364 |
|
702 |
||
FDA PMTA (e) |
|
1,957 |
|
- |
||
Non-cash asset impairment (f) |
|
6,300 |
|
- |
||
Adjusted EBITDA | $ |
24,726 |
$ |
30,004 |
||
(a) Represents costs associated with corporate restructuring, including severance. |
(b) Represents cost associated with scoping new ERP and CRM systems. |
(c) Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units. |
(d) Represents the fees incurred for transaction expenses. |
(e) Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA"). |
(f) Represents impairment of investment in dosist. |
Schedule B | |||||||
Reconciliation of GAAP diluted EPS to Adjusted diluted EPS | |||||||
(dollars in thousands except share data) | |||||||
(unaudited) | Three Months Ended |
||||||
|
|||||||
2022 |
|
2021 |
|||||
GAAP EPS | $ |
0.30 |
$ |
0.73 |
|
||
Corporate restructuring (a) |
|
0.01 |
|
- |
|
||
ERP/CRM (b) |
|
0.03 |
|
- |
|
||
Stock options, restricted stock, and incentives expense (c) |
|
0.05 |
|
0.09 |
|
||
Transactional expenses (d) |
|
0.01 |
|
0.02 |
|
||
FDA PMTA (e) |
|
0.07 |
|
- |
|
||
Non-cash asset impairment (f) |
|
0.23 |
|
- |
|
||
Tax (expense) benefit (g) |
|
0.00 |
|
(0.01 |
) |
||
Adjusted diluted EPS | $ |
0.70 |
$ |
0.84 |
|
||
Totals may not foot due to rounding |
(a) Represents costs associated with corporate restructuring, including severance, tax effected at the quarterly tax rate. | |||
(b) Represents cost associated with scoping new ERP and CRM systems tax effected at the quarterly tax rate. | |||
(c) Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs tax effected at the quarterly tax rate. | |||
(d) Represents the fees incurred for transaction expenses tax effected at the quarterly tax rate. | |||
(e) Represents costs associated with applications related to the FDA PMTA tax effected at the quarterly tax rate. | |||
(f) Represents impairment of investment in dosist tax effected at the quarterly tax rate. | |||
(g) Represents adjustment from quarterly tax rate to annual projected tax rate of |
|||
Schedule C | ||||||||||||||||||||||||
Reconciliation of GAAP Operating Income to Adjusted Operating Income | ||||||||||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
(unaudited) | ||||||||||||||||||||||||
Consolidated |
|
Zig-Zag Products |
|
Stoker's Products |
|
NewGen Products |
||||||||||||||||||
2nd Quarter |
|
2nd Quarter |
|
2nd Quarter |
|
2nd Quarter |
|
2nd Quarter |
|
2nd Quarter |
|
2nd Quarter |
|
2nd Quarter |
||||||||||
2022 |
|
2021 |
|
2022 |
|
2021 |
|
2022 |
|
2021 |
|
2022 |
|
2021 |
||||||||||
Net sales | $ |
102,925 |
$ |
122,643 |
$ |
46,226 |
$ |
47,202 |
$ |
33,588 |
$ |
33,369 |
$ |
23,111 |
$ |
42,072 |
||||||||
Gross profit | $ |
51,469 |
$ |
59,973 |
$ |
26,430 |
$ |
27,743 |
$ |
18,079 |
$ |
18,146 |
$ |
6,960 |
$ |
14,084 |
||||||||
Operating income | $ |
18,146 |
$ |
24,879 |
$ |
18,503 |
$ |
21,338 |
$ |
13,378 |
$ |
13,826 |
$ |
552 |
$ |
1,657 |
||||||||
Adjustments: | ||||||||||||||||||||||||
Corporate restructuring |
|
270 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
||||||||
ERP/CRM |
|
861 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
||||||||||
Transactional expenses |
|
364 |
|
702 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
||||||||
FDA PMTA |
|
1,957 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
||||||||
Adjusted operating income | $ |
21,598 |
$ |
25,581 |
$ |
18,503 |
$ |
21,338 |
$ |
13,378 |
$ |
13,826 |
$ |
552 |
$ |
1,657 |
||||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20220727005234/en/
Investor Contacts
502.774.9238
ir@tpbi.com
Source:
FAQ
What were the financial results for Turning Point Brands (TPB) in Q2 2022?
How did Zig-Zag products perform in Q2 2022?
What is the outlook for Turning Point Brands in 2022?
What caused the decline in NewGen product sales for TPB?